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ABSTRACT 
 
Tuberculosis is one of the top ten causes of death, and there is no simple way of predicting 
disease outcomes. The purpose of this project was to determine whether neutrophil-related 
proteins, S100A8 and CXCL5 correlate with the levels of Mycobacterium tuberculosis, and 
explore whether these proteins could be used as indicators of disease progression. Their 
concentrations in the lungs were calculated using sandwich ELISAs. The bacterial burdens in the 
lungs were calculated from Colony Forming Units (CFUs) grown on agar plates. Mice were 
weighed weekly. Final analyses showed no correlation between neutrophil chemokines and M. 
tuberculosis burden, and that mice had no weight loss throughout the experimental timeframe. 
Therefore, when there is a weight gain, lung concentrations of S100A8 and CXCL5 cannot be 
used as indicators of disease progression in TB.  
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BACKGROUND 
 
 
Tuberculosis Introduction 
 
Tuberculosis (TB) is an infectious disease of the lungs, caused by the bacterium 
Mycobacterium tuberculosis and is common in third world countries. According to the World 
Health Organization, TB is one of the top ten causes of death worldwide (WHO, 2018). Each 
year, 9 million people are diagnosed with TB, and 1.5 million die from the disease (Nouailles et 
al., 2014). TB is also more common and deadly for those co-infected with HIV due to their 
already compromised immune system. Therefore, TB is the leading cause of death in HIV-
positive patients (WHO, 2018). The majority of TB cases occur in Africa and Asia, with about 
half of the new cases occurring in Bangladesh, India, Pakistan, China, India, and Indonesia (Dye, 
2006). Since TB is such a large global health issue, the World Health Organization has set a goal 
to reduce the number of TB cases worldwide by 95% by 2035 (Sulis et al., 2014).   
 
According to the World Health Organization, only 10% of those exposed to M. 
tuberculosis will contract the disease, and the other 90% will never get sick (WHO, 2018). Men 
are more than two times more likely than women to develop active TB (Dye, 2006). The 
bacterium Mycobacterium tuberculosis has co-evolved with humans for thousands of years and 
humans are the main host for M. tuberculosis (Niemann & Supply, 2014). The main method for 
contracting M. tuberculosis is exposure to someone else with active TB. The bacteria spreads 
person to person through aerosolized droplets generated by coughing, sneezing, or talking 
(American Lung Association, 2018). The bacteria can stay in the air for a couple of hours, 
increasing the risk of another person inhaling the bacteria (Heemskerk et al., 2015). 
 
Following exposure via aerosols, bacilli spread from the lungs to other parts of the body 
including the pleura, lymph nodes, bones, and urogenital system in susceptible individuals 
(Adzic-Vukicevic et al., 2017). The common symptoms of TB include a lasting cough, coughing 
up blood, malaise, fatigue, weight loss, chills, anorexia, fever, and night sweats (Campbell & 
Bah-Sow, 2006). Without treatment, TB is fatal for 53%-83% of patients diagnosed with 
pulmonary TB (Tiemersma et al., 2011).  
 
Once the M. tuberculosis enters the lung alveoli, they are engulfed by macrophages. The 
macrophages either lyse the bacteria resulting in no infection, or the bacteria replicate inside the 
macrophages. In the latter case, when the macrophage dies, the multiplied M. tuberculosis is 
released into the surrounding area infecting more cells, resulting in pulmonary TB (CDC, n.d.). 
The presence of M. tuberculosis in the lungs results in a recruitment of T cells and inflammatory 
cells. These T cells and inflammatory cells surround the bacteria creating granulomas. In 
susceptible individuals, M. tuberculosis infection of the lungs results in necrosis of both the 
macrophages and the pulmonary tissue, which makes lung necrosis a good indication of the 
progression of the infection (Kramnik & Beamer, 2016). Necrosis occurs at these granulomas 
due to the death of macrophages that occurs from M. tuberculosis stimulating signal pathways 
that induce cell death. The areas of necrosis become ideal locations for the M. tuberculosis to 
replicate (Kramnik & Beamer, 2016). The bacteria are also taken up by the bloodstream within 
the first 3-6 weeks of infection, before the start of necrosis, which spreads the infection to 
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different parts of the body. This process is known as dissemination and leads to extrapulmonary 
TB. 
 
Tuberculosis is diagnosed using either a rapid molecular test, a sputum smear, or a 
culture-based method (WHO, 2018b). The best method for diagnosing TB is through a rapid 
molecular test, which provides the most accurate results within two hours. The sputum smear 
test, used for over 100 years, requires the collection of a sputum sample that is then analyzed 
with a microscope to examine for M. tuberculosis. The culture-based method is used more as a 
secondary reference because it can take up to 12 weeks to determine the results (WHO, 2018b). 
The use of rapid molecular tests is becoming more common worldwide, but the sputum smear 
test and culture-based methods are still used to monitor the disease progression. 
 
TB Treatment and Prevention  
 
Tuberculosis is curable and preventable in some individuals with proper treatment. TB is 
treated by giving a combination of antimicrobials over six to nine months. The common drugs 
prescribed include isoniazid, rifampin, ethambutol, and pyrazinamide (CDC, 2016). However, if 
this treatment plan is not completed, the disease can reoccur, and the surviving bacilli can be 
drug resistant (Kurz et al., 2016). M. tuberculosis resistant to both of the first-line treatments, 
isoniazid and rifampin, are considered to be multidrug resistant TB. Treating multidrug resistant 
TB is difficult and requires chemotherapy on top of a second line drug treatment (WHO, 2018). 
Treating multidrug resistant TB only has a 48% success rate (Kurz et al., 2016).  
 
Bacille Calmette-Guerin (BCG) is the only currently approved vaccine for tuberculosis, 
and it is usually given to children in high risk areas where TB is prevalent. This vaccine is an 
attenuated form of Mycobacterium bovis bacteria, and was first used in children almost one 
hundred years ago (Orme, 2014). This vaccine is good at preventing disseminated TB in 
children, but has variable protection against pulmonary TB in adults, who make up most of the 
TB cases (Van Der Meeren et al., 2018). The efficacy of the BCG vaccine on pulmonary TB in 
adults is between 0-80% (Pai et al., 2016). Since the BCG is not very effective in adults, there is 
currently much research focused on finding a new TB vaccine or finding ways to improve the 
BCG vaccine to generate durable immunity. Due to the variability in TB infections, researching 
new vaccines is very costly, time consuming, and has more obstacles than most vaccine research. 
One of the biggest obstacles is the lack of an animal model that shows the full variability of TB 
seen in human patients (Pai et al., 2016). Therefore, much research also focuses on creating 
genetically diverse mouse models that accurately reflect the wide variability of M. tuberculosis 
infections seen in humans.  
 
 Despite these obstacles, there are many TB vaccines in clinical trials. One vaccine 
currently in phase IIB clinical trials is M72/ASOIE vaccine, which is designed to prevent active 
TB in uninfected individuals or those with latent TB (Pai et al., 2016). The major component of 
this vaccine is two proteins that are present in the M. tuberculosis bacteria (Van Der Meeren et 
al., 2018). During the Phase IIB clinical trial, the efficacy of the vaccine was tested on 
individuals in Africa, concluding the vaccine had a 54% efficacy with no major side effects (Van 
Der Meeren et al., 2018). Therefore, more research will be continued with this vaccine in the 
future.  
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TB Susceptibility 
 
The degrees of TB disease lie on a spectrum. One end of the spectrum is known as latent 
TB, where the individual is believed to be infected with M. tuberculosis but is asymptomatic.  
These individuals are non-contagious, but are at risk of developing active TB. It is estimated that 
90% of those infected with M. tuberculosis are in the latent phase, or the bacteria gets destroyed 
by the immune system (Heemskerk et al., 2015). In latent TB, macrophages engulf and surround 
the bacteria to produce areas called granulomas. Granulomas can exist for a long period, 
potentially the rest of the person's life, and sometimes never turn into active TB (CDC, n.d.). 
However, in susceptible individuals M. tuberculosis can eventually overpower the immune 
system causing the granulomas to break, creating active TB (CDC, n.d.).  
 
Incipient TB is an intermediate phase of TB. Incipient TB refers to the early stages of the 
infection during its change from latent to active. During incipient TB the patient is still 
asymptomatic, but is considered to be in a disease state (Achkar & Jenny-Avital, 2011). Incipient 
TB is defined by the presence of a 2 cm2 opacity seen in a chest X-ray on an asymptomatic 
immunocompetent individual, where the only potential explanation for the opacity is TB (Achkar 
& Jenny-Avital, 2011).   
 
In active TB, the M. tuberculosis replicates to very high levels, and the infection is 
contagious. Active TB most commonly occurs in the lungs and is also known as pulmonary TB. 
During pulmonary TB, the individual experiences coughing, coughing up blood, weight loss, and 
fever. These individuals might have a positive sputum smear test (Campbell & Bah-Sow, 2006). 
When an individual has active TB, the infection can also spread to other parts of the body, 
known as extra-pulmonary TB.  
 
Dissemination of M. tuberculosis can also occur very rapidly, which results in fulminant 
TB. During fulminant TB there is a rapid onset of the disease which can lead to septic shock and 
multiorgan failure (Bridges & Bedimo, 2006). Fulminant TB is a rare form of the disease, but it 
occurs more frequently in those who are HIV-positive since they are already 
immunocompromised (Bridges & Bedimo, 2006).  
 
This complex symptomology results in a range of super-susceptible, susceptible, and 
resistant individuals. It is widely accepted that this range of susceptibility is due to genetics. The 
idea that tuberculosis susceptibility is partly genetic is supported through the studies of 
monozygotic and dizygotic twins infected with M. tuberculosis. Monozygotic twins are equally 
susceptible to TB, whereas the susceptibility of TB in dizygotic twins is variable (Smith et al., 
2016). However, the mechanism by which genes play a role in the susceptibility remains 
unknown. Genetic variability among strains of the M. tuberculosis bacteria are also responsible 
for the range in susceptibility and virulence (Pai et al., 2016). 
 
TB Mouse Models 
 
Two major types of mouse models are used in medical research, inbred strains and 
outbred strains. Inbred strains have been used for decades in infectious disease research, 
including infection experiments with M. tuberculosis. Inbred strains are often used because they 
are cost effective, immunocompetent, readily available for purchase, genetically stable, and 
easily genetically manipulated. Inbred mice are genetically stable because each individual mouse 
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is genetically identical the others, allowing for experimental reproducibility (Yeadon, 2013). 
However, since the inbred strains are composed of identical individuals, there is also a lack of 
diversity in the mouse populations, which does not match the diversity of the human population. 
Therefore, recent research has focused on creating a diversity outbred (DO) population of mice. 
The DO mouse population is created from eight inbred strains known as the “founder strains,” 
which were used in this project. These DO populations are genetically heterogeneous, creating a 
large genetic diversity within the population (Churchill et al., 2012). Since there is a large 
genetic diversity among DO mice, they are a better model for studying the relationship between 
infectious disease and genetics. 
 
Since the naturally occurring host for M. tuberculosis is humans, it is well known that 
one or two inbred strains mice cannot model the variable susceptibility observed across the 
human population. Unfortunately, scientists in the TB field have generalized the responses of 1-2 
inbred mouse strains to all mice, creating the following dogma: Mice are more resistant to TB 
than humans; Mice can handle higher bacterial burden than humans; and mice form different 
granulomas compared to humans (Dharmadhikari & Nardell, 2008; Cooper, 2015). Finally, it is 
already known that the susceptibility of TB largely depends on both the host and bacterial 
genetics. Many different mouse strains are affected differently by TB due to their genetics, which 
leads to inconsistent results among studies (Fonseca et al., 2017). Also, since mice are not 
natural hosts of M. tuberculosis, laboratories often use modified strains of M. tuberculosis that 
can infect the mice (Fonseca et al., 2017).  
 
Despite these setbacks, mouse models are still widely used for TB research since they are 
the most understood model, and researchers continue to create a more humanized mouse model 
that reflects human M. tuberculosis infection (Fonseca et al., 2017). One advantages of mouse 
models is the ability to engineer the mice to over-express (knock-in) or under-express (knock-
out) a desired gene. This ability to genetically modify the mice has played a big role in 
determining which genes play a role in TB susceptibility (Dharmadhikari & Nardell, 2008). 
Therefore, the creation of a mouse strain that mimics the susceptibility of M. tuberculosis in 
humans would help in research.  
 
TB Mouse Model Founder Strains 
 
 As mentioned above, the DO mouse population was created from eight inbred founder 
strains for the purpose of increasing genetic diversity in the experimental mouse model. The 
eight founder strains were: CAST/EiJ, PWK/PhJ, NOD/ShiLtJ, A/J, C57BL/6, NZO/HiLtJ, 
129S1/SvImJ, and WSB/EiJ.  Within each strain, individual mice are genetically identical and 
homozygous at all loci. Across each strain, these eight founders are highly genetically different 
which is why they were selected to then subsequently breed together to generate the DO 
population. The CAST/EiJ, PWK/PhJ, and WSB/EiJ strains were originally derived from wild 
mice captured from different locations across the globe (Collaborative Cross Consortium, 2012). 
The CAST/EiJ mice were derived by inbreeding mice found in a warehouse in Thailand 
(https://www.jax.org). The WSB/EiJ strain was formed by inbreeding mice captured in 
Maryland, and the PWK/PhJ strain was inbred in the Czech Republic (https://www.jax.org).  The 
NOD/ShiLtJ strain is often used when studying the effects of being immunocompromised, 
because the NOD/ShiLtJ strain has defective cytokine productions from macrophages, as well as 
insufficient natural killer (NK) cell production, and defective antigen presentation under certain 
stimuli (https://www.jax.org). All eight of these founder strains were used in this MQP project.  
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S100A8 as an Inflammatory Marker for Active TB 
 
S100A8, also known as calgranulin-A, is a calcium-binding protein containing two 
binding motifs. It is encoded by the S100A8 gene in humans and in mice. The genes that encode 
S100A8 are in the S100 family of proteins (Schäfer & Heizmann, 1996).  S100A8 can form a 
heterodimer with protein S100A9 to form a protein called calprotectin.  S100A8 and A9 are 
prominent players in innate immunity (Nacken et al., 2003; Roth et al., 2004). S100A8 is 
upregulated in the serum of individuals with inflammatory diseases or sepsis, which means it can 
be used as a biomarker for inflammatory disease and during disease diagnosis (Wang et al., 
2018). Previous research indicates that the concentration of S100A8 in the serum of active TB 
patients directly correlates with lung damage and morbidity as experienced by TB patients 
(Gopal et al., 2013). Therefore, S100A8 can be used to determine the progression of active TB. 
Currently, there are no simple and fast tests to determine the difference between latent and active 
TB, so perhaps assaying S100A8 levels could provide such a test (Gopal et al., 2013).  
 
The S100A8 protein is stored in neutrophils and monocytes.  During trauma or infection, 
the neutrophils and monocytes upregulate and secrete S100A8 to create an inflammatory 
response (Wang et al., 2018). The release of S100A8 also results in the recruitment of 
leukocytes, and signals the neutrophils and macrophages to release cytokines (Wang et al., 
2018). While inflammation is part of our internal defense against pathogens, excess and 
prolonged inflammation can lead to cell death and tissue damage (Wang et al., 2018). The 
amount of S100A8 is normally regulated through a negative feedback loop, but when this 
negative loop is not working, the excessive inflammation can cause damage. High levels of 
S100A8 are often found in patients with septic shock and inflammatory damage (Wang et al., 
2018).  
 
 Since excess S100A8 associates with disease progression, perhaps it could be used as a 
target protein for disease therapy. Therapeutically decreasing the levels of S100A8 could 
decrease inflammation, which could help decrease the stress on the organs, and decrease the 
damage caused by inflammation (Wang et al., 2018). Therefore, S100A8 could potentially be 
used as a target for treating active TB. Decreasing S100A8 in active TB patients could decrease 
lung damage caused by the inflammation, without affecting adaptive immunity against the M. 
tuberculosis (Gopal et al., 2013).  
 
CXCL5 and TB 
 
CXCL5 is lipopolysaccharide-induced ligand from the CXC cytokine family, responsible 
for neutrophil recruitment (Mei et al., 2010). CXCL5 is commonly found in areas of 
inflammation, especially in the lungs (Mei et al., 2010). In mice, the CXCL5 is produced 
regularly by the platelets in the blood. During times of inflammation, the alveolar cell types I and 
type II upregulate the production CXCL5 in the lungs (Nouailles et al., 2014). Although it is 
known that CXCL5 is involved in lung inflammation, the specific details have not been fully 
studied (Mei et al., 2010). In the case of Escherichia coli pneumonia lung infections, the CXCL5 
recruits more neutrophils to the area compared to other members of the CXC cytokine family. In 
humans, there is often a large abundance of CXCL5 in the lung fluids during a time of infection 
(Mei et al., 2010). The increased number of neutrophils results in inflammation in the lungs. 
Therefore, there is a correlation between CXCL5 concentration and lung damage, which can lead 
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to death of the host (Mei et al., 2010). Currently, CXCL5 has been predominantly studied in 
murine models. Murine CXCL5 closely resembled human CXCL5, and human CXCL5 is also 
produced by the alveolar cells, but research has not demonstrated that human CXCL5 also results 
in neutrophil recruitment during lung infections (Nouailles et al., 2014).  
 
CXCL5 is upregulated in the lungs of patients with active TB. In a previous study, work 
from the Beamer laboratory showed that some DO mice infected with M. tuberculosis had high 
concentrations of CXCL5 in the lungs that occurred only in DO individuals that developed early 
morbidity and died after only a few weeks after infection (Muhammad et al., 2015). The same 
work and additional unpublished observations (not shown) have identified lung CXCL5 as a 
strong and positive correlate of pulmonary TB disease in mice.  
 
ELISAs 
 
Enzyme-linked immunosorbent assay (ELISA) is a method to quantify molecules 
including protein, peptides, or hormones in a complex sample. In this project, ELISAs were used 
to quantify S100A8 and CXCL5 in lung samples from M. tuberculosis-infected mice. This assay 
is commonly performed on a 96-well polystyrene plate. The sandwich ELISA is the most 
sensitive type of ELISA (ThermoFischer Scientific, n.d.). During a sandwich ELISA, a capture 
antibody against the target protein is coated onto the ELISA well. Then, the sample containing 
the target protein is added.  The target protein binds to the antibody coat, and the rest of the 
unbound proteins are washed away. Next, a secondary detection antibody is added. The detection 
antibody binds to the other end of the target protein (Sino Biological, n.d.), sandwiching the 
target protein between two antibodies. The secondary antibody is conjugated to an enzyme, such 
as horseradish peroxidase (HRP) or alkaline phosphatase (AP), that forms a color when mixed 
with a colorless reagent solution. The amount of color produced in the well is proportional to the 
amount of target protein present. The ELISA plate is read with a spectrophotometer to produce 
absorbance values associated with the concentration of the desired reagent. When combined with 
standard curves of known protein concentrations, the mathematical relationship between 
absorbance of CXCL5 or S100A8 in lung samples can be derived and calculated using linear or 
polynomial regression models.  
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PROJECT PURPOSE 
The purpose of this project was to determine whether neutrophil-related proteins, S100A8 
and CXCL5 correlate with the levels of M. tuberculosis in the lungs, and explore whether these 
proteins could be used as indicators of disease progression in the eight founder strains of the DO 
population.  The concentrations of S100A8 and CXCL5 in the lungs were calculated using 
sandwich ELISAs. The bacterial burdens in lungs were calculated from Colony Forming Units 
(CFUs) grown on agar plates and the mice were weighed weekly. Based on work in the DO 
population (Muhammad et al., 2015) and previous work using the eight founder strains (Smith et 
al., 2016) we expected that the concentrations of S100A8 and CXCL5 would correlate with 
weight loss, early morbidity, and with M. tuberculosis lung burden. Since little M. tuberculosis 
studies have been done on mouse strains other than C57BL/6, 129, and A/J strains, any results 
obtained with new strains will be interesting.  If this project is successful, it will help develop a 
method for determining the disease state of TB patients.  
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METHODS 
Mouse Infection and Sample Collections  
 
  CAST/EiJ, PWK/PhJ, NOD/ShiLtJ, A/J, C57BL/6, NZO/HiLtJ, 129S1/SvImJ, and 
WSB/EiJ mouse strains were purchased from The Jackson Laboratory in Bar Harbor, Maine. The 
mice were kept in a Biosafety Level 3 laboratory at The Ohio State University. The mice were 
infected by aerosolized M. tuberculosis Erdman so that each mouse was exposed to 25-50 CFUs 
of M. tuberculosis (Beamer et al., 2008). The mice were weighed every week. Groups of 3-5 
mice were euthanized by CO2, and blood and lungs from each mouse were collected at 20 days, 
30 days, and 40 days post infection. The blood was clotted and centrifuged for 10 minutes at 
3,000 RPMs, and then serum collected, filter sterilized, and frozen. Three lung lobes were 
homogenized in sterile phosphate buffered saline, serially diluted, and plated in technical 
replicates on 7H11 agar supplemented with OADC, incubated at 37°C for 3 weeks, and M. 
tuberculosis colony forming units were counted (Beamer et al., 2008). The remaining lung 
homogenates were then filter sterilized and stored -80°C. The remaining lung lobes were inflated 
with 10% neutral buffered formalin, fixed for 3 weeks, and embedded in paraffin, sectioned, and 
stained using hematoxylin and eosin. Infection, tissue harvest, and CFU counts were performed 
at The Ohio State University. The frozen lung and serum samples were sent to the Tufts 
Cumming School of Veterinary Medicine for analysis. These experiments were approved by 
Tufts University Institutional Animal Care and Use Committee numbers (IACUC numbers 
G2012-53; G2012-151; G2015-33).  
  
ELISA  
 
Filtered lung homogenates were tested for cytokines. S100A8 and CXCL5 ELISA kits 
were purchased from R&D Systems: A Biotechne Brand, and optimized for our laboratory 
conditions before testing samples. The 96-well plates were first coated with 100 L of 4 g/mL 
of the capture antibody. For the CXCL5 assay, two vials of capture (Lot numbers GNZ0413111 
and GNZ0516081) were used. The coated ELISA plates were incubated at 4°C overnight. The 
next day, the unbound capture antibodies were removed from the plate. Then, all of the ELISA 
plates were blocked with 200 L of 1% BSA and left at room temperature to incubate for one 
hour. The BSA was then removed from the plate and the samples were added. For each plate, the 
first three columns were the CXCL5 standard with a 4 ng/mL concentration in the first row, and 
then a one to one serial dilution proceeding down the column, until the last row which a blank 
filled with 1% BSA. The remaining wells were filled with 100 L of 1:10, 1:100, and 1:1,000 
serially diluted lung or serum samples. The samples were incubated at 4°C for 72 hours. After 
the incubation period, the samples were removed from the plates, and all of the plates were 
washed 6 times with 1X PBST. After washing, the 100 L of a 0.05 g/mL detection antibody 
(Lot numbers BES0716081 and BES0715071) was added to each of the wells. The detection 
antibody was incubated at room temperature for two hours. After the incubation period, the 
plates were washed again with 1X PBST 6 times. Then, 100 L of 5 L/mL streptavidin-HRP 
was added to each of the wells and incubated at room temperature for 20 minutes under tin foil to 
prevent exposure to light. The HRP was then removed from the plates, and the plates were 
washed again using the 1X PBST 6 times. Next, 100 L of TMB was added to each of the wells, 
and the plates incubated at room temperature for 20 minutes under tinfoil. After 20 minutes, 100 
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L of 2.5% HCl was added to each well to stop the reaction. The optical density of each plate 
was then measured using a microplate reader set to 450 nm. The exact same procedure was 
followed for the detection of S100A8. The S100A8 capture antibody had lot number 
CHFW0117111 and the detection antibody was lot number WKF0417111.  
 
Light Microscopy  
 
One lung sample from each strain was examined under an Olympus light microscopy. The 
samples collected 30 days post infection were used, except for WSB/EiJ. The sample collected 
20 days post-infection was used for WSB/EiJ. The areas of inflammation were examined at 4X, 
10X, and 20X magnification. Images of all of these slides were taken using Infinity Capture 
software. The relative area of inflammation in each strain was compared at 4X magnification.  
 
Statistics  
 
Before analysis, all of the data was checked for single outliers using Grubbs’ test on GraphPad 
Outlier Calculator. Eight outliers were identified and censored. Analysis of multiple variables 
(for example mouse strains, proteins, and time) ANOVA was used following Tukey’s multiple 
comparison test to determine statistical significance. To identify correlations between S100A8 
and CXCL5 and M. tuberculosis burden; and S100A8 with CXCL5, Spearman’s test was used. 
All data with a p-value of 0.05 or lower was deemed to be statistically significant. All of the final 
graphs presented were made using Prism 8. 
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RESULTS 
 
 
The purpose of this MQP was to determine whether the concentrations of neutrophil-
related chemokines S100A8 and CXCL5 correlate with M. tuberculosis lung burden, or with 
each other, or with disease indicators in the eight founder strains. M. tuberculosis burden was 
measured by colony forming units (CFU). The concentrations of S100A8 and CXCL5 were 
quantified by sandwich ELISAs, and correlated with M. tuberculosis CFUs in lung samples. 
Eight different mouse strains, CAST/EiJ, PWK/PhJ, NOD/ShiLtJ, A/J, C57BL/6, NZO/HiLtJ, 
129S1/SvImJ, and WSB/EiJ, now referred to as CAST, PWK, NOD, A/J, B6, NZO, 129, WSB 
respectively, were analyzed to mimic the wide-ranging genetic variance seen in the human 
population.  
 
Before this project began, all mouse strains were infected with an average of 31 CFUs of 
aerosolized M. tuberculosis Erdman at The Ohio State University. During those experiments, 
mice were weighed at least weekly, and 3-5 mice per strain were euthanized and lungs and serum 
collected at 20 days, 30 days, and 40 days post-infection. Lungs were processed to determine M. 
tuberculosis CFUs. Figure-1 below shows the CFU results from this previous research. The A/J 
strain shows significantly higher M. tuberculosis burden at day 30 post-infection relative to day 
20 post-infection (p-value= <0.0001) and day 40 post-infection (p-value= <0.0001). The NZO 
strain showed significantly lower levels of M. tuberculosis at day 40 post-infection relative to 
days 20 and 30 post-infection (p-values= 0.0049 and 0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: M. tuberculosis Bacterial Burden in Mouse Lungs at 20, 30, and 40 Days Post-
Infection. M. tuberculosis CFUs from serially diluted lung homogenates of individual mice were 
assayed by growth on agar, and colonies counted after 3 weeks incubation at 37ºC. Results shown 
are averages of 3-5 mice per strain per time-point, and standard error. The first bar for each strain 
is 20 days post infection. The second bar is 30 days post infection. The third bar is 40 days post 
infection. The statistical significance between time points was done through a Tukey’s multiple 
comparison test and is denoted by the asterisks. 
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All of the mice were weighed in grams at days 20, 30, and 40 days post-infection. 
Figure-2 shows the average weights of all the strains over time. All eight of the strains gained 
weight over time, with the CAST strain showing statistically significant weight gain when 
comparing the weight at day 40 post-with days 20 and 30-post infection (p-values= 0.0007 and 
0.0075 respectively). No weight data was available for WSB. The weight increase corresponds 
with a decrease in M. tuberculosis burden in CAST, NOD, B6, NZO, and 129.  
 
 
 
Figure-2: Weight (grams) of mice at 20, 30, and 40 Days Post-Infection. This figure shows the average 
weight in grams over time. The error bars represent the standard error of the mean. The first bar for each 
strain is 20 days post-infection, the second bar is 30 days post-infection, and the third bar is 40 days post-
infection. The statistical significance between time points was done through a Tukey’s multiple comparison 
test and is denoted by the asterisks. 
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The concentrations of neutrophil-related chemokines S100A8 (Figure-3) and CXCL5 
(Figure-4) present in the lungs of M. tuberculosis infected mice were assayed by sandwich 
ELISAs.  The average concentrations are shown in pg/mL at 20 days, 30 days, and 40 days post 
infection. For S100A8, 7 of the 8 strains tested showed an increase at day 30 post-infection 
relative to day-20, and the increase is statistically significant in the CAST and A/J strains (p-
values= 0.0065 and 0.0140 respectively).  The pattern of increasing S100A8 at day 30 post-
infection reflects the pattern of M. tuberculosis in only two strains, PWK and A/J. In the other 6 
strains the patterns of S100A8 and M. tuberculosis were not similar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3: Lung Concentrations of Protein S100A8 (pg/mL) in Mouse Lungs at 20, 30, and 40 
Days Post-Infection. The average lung concentrations of S100A8 measured by ELISAs in pg/mL 
over time. The error bars represent the standard error of the mean. The first bar for each strain is 
20 days post-infection, the second bar is 30 days post-infection, and the third bar is 40 days post-
infection. The statistical significance between time points was done through a Tukey’s multiple 
comparison test, and is denoted by the asterisks.  
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For protein CXCL5 (Figure-4), 4 of 8 strains increased in CXCL5 over time (NOD, A/J, 
B6, and WSB). This pattern corresponds with a decrease in M. tuberculosis in NOD and B6. The 
remaining 6 strains do not show a similarity in pattern between CXCL5 and M. tuberculosis. 
Two strains showed a decreased in CXCL5 over time (NZO and 129) with it being statistically 
significant at days 30 and 40 post-infection relative to day 20 post-infection (p-values= 0.0402 
and 0.0020 respectively). CAST and PWK show a trough at day 30 post-infection which is 
statistically significant in PWK when compared to day 20 and day 40 post-infection (p-values= 
0.0277 and 0.0010 respectively).  
 
 
 
Figure-4:  Lung Concentrations of Chemokine CXCL5 (pg/mL) Determined by ELISAs at 
20, 30, and 40 Days Post-Infection. The average concentrations (pg/mL) of CXCL5 measured by 
ELISAs in lung samples over time. The error bars represent standard error of the mean. The first 
bar for each strain is 20 days post-infection, the second bar is 30 days post infection, and the third 
bar is 40 days post-infection. The statistical significance between time points was done through a 
Tukey’s multiple comparison test, and is denoted by the asterisks.  
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Plots of the levels of M. tuberculosis lung burden (CFUs, X-axis) versus lung 
concentrations of neutrophil-related chemokines CXCL5 and S100A8 (pg/mL, Y-axis) at days 
20, 30, and 40 post-infection are shown in Figure-5. Each color represents a different mouse 
strain, and matches the color coding in the previous figures. All 8 mouse strains show no 
statistically significant correlations when analyzing all 8 strains together.  
 
 
 
Figure-5: Correlation of Lung M. tuberculosis Burden vs CXCL5, M. tuberculosis Levels vs 
S100A8; and CXCL5 vs S100A8, for All 8 Mouse Strains at each time point. Panels A-C 
show CXCL5 versus M.tb burden at days 20, 30, and 40, respectively.  Panels D-F show S100A8 
vs burden at days 20, 30, and 40, respectively.  Panels G-I show CXCL5 vs S100A8 at days 20, 
30, and 40, respectively 
 
Lung lobes of all the mouse strains were sectioned at Tufts University Cummings School 
of Veterinary Medicine and stained with hematoxylin and eosin. These samples were then 
examined under 4X magnification (Figure-6). The lung lobes of each strain were examined at 
30-days post-infection, expect the WSB sample was taken at 20 days post-infection. The areas 
that are stained a dark purple are the areas of inflammation from M. tuberculosis. PWK, A/J, and 
B6 show the largest area of inflammation at 4X magnification. The high area of inflammation 
corresponds with a large M. tuberculosis burden in A/J, but not the other strains. CAST and 129 
show the smallest area of inflammation in the lungs at 30-days post-infection.  
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Figure-6: Light Microscopy of Lung Samples of Each Strain at 4X Magnification. This figure shows a 
lung sample seen at 4X magnification for each of the strains. For all of the panels, the dark purple staining 
is the area of inflammation. Panel A: Cast, Panel B: PWK, Panel C: NOD, Panel D: A/J, Panel E: B6, 
Panel F: NZO, Panel G: 129, and Panel H: WSB. All of the lung samples were taken at 30-days post-
infection, except for WSB which was taken at 20-days post-infection. 
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DISCUSSION 
 
Based on previous work in our laboratory and others (Beamer et al., 2008; Smith et al., 
2016), we hypothesized that some inbred founder mouse strains would develop weight loss, and 
that M. tuberculosis bacterial burden would correlate with S100A8 and CXCL5 in the lungs. The 
latter was expected because S100A8 is secreted as an inflammatory response, and CXCL5 
recruits neutrophils to the lungs during M. tuberculosis infection and is associated with lung 
damage. However, in the panel of eight inbred strains analyzed in this project (CAST, PWK, 
NOD, A/J, B6, NZO, 129, and WSB), no correlations were identified (Figure-5). For both 
S100A8 and CXCL5, the patterns of 6 out of the 8 strains did not match with a pattern seen in M. 
tuberculosis burden, and the strains that did correspond with patterns seen in M. tuberculosis 
were not the same for both S100A8 and CXCL5 (Figure-1, Figure-3, Figure-4).  
 
Previous research performed at the University of Massachusetts Medical School 
(UMMS) examined lung CFUs in the same 8 inbred mouse strains (CAST, PWK, NOD, A/J, B6, 
NZO, 129, and WSB) infected with 50-200 CFUs of M. tuberculosis H37Rv. In this research 
(Smith et al., 2016), the CFUs were examined at 3 weeks and 6 weeks post-infection, except for 
WSB which was examined at 3- and 4-weeks post-infection. All 8 strains showed an increase in 
M. tuberculosis CFUs over time with a significant difference only in the WSB strain (Smith et 
al., 2016). This result contradicts the findings presented in this MQP which shows an increase in 
only 3 strains (PWK, A/J, and WSB) (Figure-1). The research provided by Smith et al. also 
showed a weight loss in the 129 strain after 3 weeks, and in A/J and PWK strains after 6 weeks 
(Smith et al., 2016). On the other hand, this project shows a weight gain in all the strains for the 
entirety of the study.  
 
 This lack of agreement between our studies here and those of Smith et al may reflect 
differences in the initial dose of infection, the strain of M. tuberculosis used, or procedures and 
equipment used to infect the mice across institutions. The two institutions performing these two 
studies indeed used different strains of M. tuberculosis and different doses of M. tuberculosis. 
The Ohio State University used an average of 31 CFUs of M. tuberculosis Erdman dose to 
initially infect mice, while UMMS reported that mice were infected with a higher dose: 50-200 
CFUs of M. tuberculosis H37Rv (Smith et al., 2016). Both institutions used a Glas-col whole 
body exposure aerosol machine (Smith et al., 2016; Beamer et al., 2008).    
 
The Beamer laboratory at Tufts University Cummings School of Veterinary Medicine  
previously published work using the DO population of mice infected with 100 CFUs of M. 
tuberculosis Erdman (Muhammad et al., 2015), and 25 CFUs of M. tuberculosis Erdman 
(unpublished observations) using a nose-only aerosol exposure administered by a CH 
Technologies aerosol-generating machine. Both published and unpublished results determined 
that 20-50% of the DO mice developed morbidity (confirmed to be TB lung disease) within 20-
40 days post-infection, and substantial weight loss in that time frame that correlated with high M. 
tuberculosis burden, and with CXCL5 and S100A8. Therefore, we expected that this project 
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would show similar results because the eight founder strains used in these experiments are the 
parents of the DO population, and the mice were infected with the same dose and strain of M. 
tuberculosis. This could reflect differences in M. tuberculosis susceptibility between inbred 
strains (composed of genetically identical individuals and homozygous at all loci) and outbred 
population (genetically distinct individuals that are heterozygous at most loci). The main 
difference between the experimental procedure at Tufts University and The Ohio State 
University was in the machine that delivered M. tuberculosis strain Erdman: CH Technologies 
nose-only exposure at Tufts versus Glas-col whole body exposure at The Ohio State. The main 
difference in the outcomes were that some DO mice developed a diseased state of TB, 
characterized by early morbidity and weight loss. In contrast, none of the eight inbred founder 
strains used in this project lost weight and all gained weight (Figure-2). Our results here did 
successfully detect and quantify CXCL5 and S100A8 in the lungs of the 8 founder strains, but 
the levels did not correlate with M. tuberculosis burden. Taken together, these results suggest 
that S100A8 and CXCL5 are present in the lungs during M. tuberculosis infection, and that 
levels accumulate prior to weight loss due to pulmonary TB. We now speculate that weight loss 
needs to occur in order for a correlation to be seen between the chemokine concentration and M. 
tuberculosis CFUs.  
 
Since no correlations were found during this project, this has raised several questions for 
future research, including: 1) Comparing the two types of aerosol-generating equipment for 
delivering M. tuberculosis (Glas-col whole body expose and CH Technologies nose-only 
exposure) in the 8 strains investigated in this project and in the DO mice. 2)  Discovering 
additional host biomarker(s) that could correlate with and/or predict disease; 3) Investigating the 
upstream control of S100A8, CXCL5, and M. tuberculosis CFUs; and 4) Pursuing studies to 
determine whether weight loss is necessary for seeing a correlation between M. tuberculosis 
CFUs vs S100A8 or CXCL5; 5) Performing the infections in transgenic mice lacking specific 
components of the immune system to determine which host responses are important for 
containing the infections.   
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